Beta Bionics Announces Proposed $125M Public Offering Of Common Stock

Beta Bionics, Inc. (NASDAQ: BBNX) has announced a proposed underwritten public offering of $125 million in common stock, with an additional 30-day option for underwriters to purchase up to $18.75 million more. The proceeds from the offering are intended for general corporate purposes, including the commercialization of its product Mint™, expansion of manufacturing facilities, and research and development. J.P. Morgan, Piper Sandler, Wells Fargo Securities, and Leerink Partners are the joint book-running managers for the offering.